Defactinib
id:
defactinib-285-17631309
title:
Defactinib
text:
Defactinib is an inhibitor of PTK2, also known as focal adhesion kinase (FAK), Pyk2, and MELK which was developed by Pfizer and licensed to Verastem Oncology as a potential treatment for solid tumors. Development for mesothelioma was discontinued in 2015 due to lack of efficacy in a placebo-controlled phase II trial. Subsequent research in patients with specific NF2 mutations also found limited activity. As of 2022, it remains in trials in combination with other medications for other types of ca
brand slug:
wiki
category slug:
encyclopedia
description:
Pharmaceutical
original url:
https://en.wikipedia.org/wiki/Defactinib
date created:
date modified:
2022-06-09T00:58:39Z
main entity:
{"identifier":"Q27077009","url":"https://www.wikidata.org/entity/Q27077009"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/e/ef/Defactinib.svg","width":512,"height":393}
fields total:
13
integrity:
15